A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer.

Each cycle will be 4 weeks in length. Patients will receive Abraxane weekly for 3 weeks. Patients will not receive Abraxane during week 4 (rest week). Nexavar will be given continuously.

Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.
Breast Cancer
DRUG: Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|DRUG: Sorafenib (Nexavar)
To evaluate the progression-free survival (PFS)and duration of response of the combination of weekly Abraxane and continuous Nexavar as first-line treatment for patients with locally advanced or metastatic breast cancer., Survival every 3 months for two years starting from the end of study date. Duration of response every 8 weeks while on treatment.
To evaluate the response rate., Every 8 weeks while on study treatment.|Evaluate the 1 and 2 year survival rate., Every 3 months for 2 years starting from the end of therapy visit date|Evaluate the toxicities of the combination of Abraxane and Nexavar, At each clinic visit or if reported by subject.
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer.

Each cycle will be 4 weeks in length. Patients will receive Abraxane weekly for 3 weeks. Patients will not receive Abraxane during week 4 (rest week). Nexavar will be given continuously.

Patients will be radiologically evaluated every 8 weeks for response. Patients will continue to receive study treatment until disease progression or unacceptable toxicity.